27,000 Shares in Janux Therapeutics, Inc. $JANX Acquired by Erste Asset Management GmbH

Key Points

• Erste Asset Management GmbH invested approximately $786,000 in Janux Therapeutics by purchasing 27,000 shares during the first quarter.
• Institutional investors own 75.39% of Janux Therapeutics stock, indicating significant confidence in the company amidst various hedge fund activity.
• Janux Therapeutics has received positive analyst ratings, with a consensus rating of "Buy" and an average price target of $86.90.

Erste Asset Management GmbH bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 27,000 shares of the company's stock, valued at approximately $786,000.

Other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Janux Therapeutics by 1,574.0% during the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after acquiring an additional 1,574 shares in the last quarter. US Bancorp DE grew its holdings in Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company's stock valued at $47,000 after purchasing an additional 1,658 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the period. GF Fund Management CO. LTD. acquired a new position in Janux Therapeutics during the fourth quarter worth $59,000. Finally, FNY Investment Advisers LLC boosted its holdings in Janux Therapeutics by 6,928.6% during the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after purchasing an additional 2,425 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Performance

JANX stock traded down $0.18 on Wednesday, reaching $23.47. The company's stock had a trading volume of 84,537 shares, compared to its average volume of 931,415. The business has a fifty day simple moving average of $24.52 and a two-hundred day simple moving average of $27.44. The firm has a market cap of $1.41 billion, a PE ratio of -13.02 and a beta of 2.86. Janux Therapeutics, Inc. has a 12-month low of $21.97 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). As a group, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on JANX shares. Raymond James Financial initiated coverage on shares of Janux Therapeutics in a research report on Friday, July 11th. They set an "outperform" rating and a $65.00 price target on the stock. Piper Sandler started coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They set an "overweight" rating and a $42.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $86.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.